Galderisi, Alfonso
Carr, Alice L. J.
Martino, Mariangela
Taylor, Peter
Senior, Peter
Dayan, Colin
Funding for this research was provided by:
Division of Diabetes, Endocrinology, and Metabolic Diseases (R01DK111038)
Juvenile Diabetes Research Foundation International (3-SRA-2022-1186-S-B)
Article History
Received: 4 June 2023
Accepted: 8 August 2023
First Online: 15 September 2023
Funding
: AG’s work is supported by the Juvenile Diabetes Research Foundation (JDRF SRA-2022-1186-S-B).
: CD has lectured for or been involved as an advisor to the following companies: Novo Nordisk, Sanofi-Genzyme, Janssen, Servier, Lilly, AstraZeneca, Provention Bio, UCB, MSD, Vielo Bio, Avotres, Worg and Novartis. He also holds a patent jointly with Midatech and Provention Bio/Sanofi. The other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
: AG and ALJC drafted the initial manuscript. MM, PT, PS and CD contributed to the identification of literature, data interpretation and discussion. CD critically revised the manuscript and coordinated the working group. All authors approved the final version of this manuscript.